AU Patent

AU728257B2 — The use of lecithin-cholesterol acyltransferase (LCAT) in the treatment of atherosclerosis

Assigned to US Department of Health and Human Services · Expires 2001-01-04 · 25y expired

What this patent protects

This invention provides methods for treating atherosclerosis in a mammalian subject by increasing the activity of LCAT in the serum of the subject to a level effective to decrease the accumulation of cholesterol in the subject. Pharmaceutical dosage forms containing LCAT also are…

USPTO Abstract

This invention provides methods for treating atherosclerosis in a mammalian subject by increasing the activity of LCAT in the serum of the subject to a level effective to decrease the accumulation of cholesterol in the subject. Pharmaceutical dosage forms containing LCAT also are provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU728257B2
Jurisdiction
AU
Classification
—
Expires
2001-01-04
Drug substance claim
No
Drug product claim
No
Assignee
US Department of Health and Human Services
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.